KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2016 - 2025)

Vertex Pharmaceuticals has reported Other Non Operating Income over the past 14 years, most recently at $6.5 million for Q4 2025.

  • Quarterly results put Other Non Operating Income at $6.5 million for Q4 2025, up 143.62% from a year ago — trailing twelve months through Dec 2025 was -$7.7 million (up 91.06% YoY), and the annual figure for FY2025 was -$7.7 million, up 91.06%.
  • Other Non Operating Income for Q4 2025 was $6.5 million at Vertex Pharmaceuticals, up from -$9.8 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for VRTX hit a ceiling of $42.4 million in Q3 2021 and a floor of -$78.1 million in Q2 2022.
  • Median Other Non Operating Income over the past 5 years was -$12.4 million (2023), compared with a mean of -$13.8 million.
  • Biggest five-year swings in Other Non Operating Income: plummeted 2500.0% in 2024 and later skyrocketed 157.14% in 2025.
  • Vertex Pharmaceuticals' Other Non Operating Income stood at $7.1 million in 2021, then plummeted by 538.03% to -$31.1 million in 2022, then soared by 68.49% to -$9.8 million in 2023, then crashed by 52.04% to -$14.9 million in 2024, then soared by 143.62% to $6.5 million in 2025.
  • The last three reported values for Other Non Operating Income were $6.5 million (Q4 2025), -$9.8 million (Q3 2025), and $13.2 million (Q2 2025) per Business Quant data.